JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
Anastrozole is one of the third-generation non-steroidal aromatase inhibitors widely used in biochemical and endocrinology studies to explore estrogen biosynthesis. Aromatase is a cytochrome P450 enzyme which catalyses the conversion of androgens to estrogens in tissue-derived cell systems. Inhibition of this enzyme leads to disruption in estrogen synthesis kinetics, and is used as a molecular tool for examining steroid metabolism, hormonal regulation, and estrogen-responsive signal transduction pathways in a defined experimental system.
Anastrozole has been extensively reported in the literature for mechanistic assessment of aromatase inhibition, receptor-mediated pathway modification and endocrinologic feedback control. In vitro studies are currently addressing its interaction with oestrogen-driven molecular mechanisms, as well as comparative aromatisation inhibition profiles. At Element CRP, anastrozole for sale is provided for research purposes only and not for any clinical, human or therapeutic use.
From Pubchem
IUPAC Name:2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrileSynonym: Arimidex, Anastrole, ICI D1033Molecular Formula: C17H19N5Molecular Weight: 293.4 g/molCAS Number: 120511-73-1PubChem CID: 2187
Estrogen biosynthesis is a key regulatory component in multiple estrogen-responsive molecular systems. Suppression of estrogen synthesis has therefore been explored as a biochemical strategy for investigating hormone-dependent signaling cascades. Within structured research frameworks, anastrozole has been utilized to examine the effects of sustained aromatase inhibition on estrogen-mediated transcriptional activity and downstream pathway regulation under controlled experimental conditions.
Large, multi-center analytical frameworks, including the IBIS-II research program, generated extensive datasets evaluating long-term modulation of estrogen synthesis kinetics and estrogen-responsive molecular markers. Comparative analyses within these frameworks reported measurable differences in estrogen-receptor–associated signaling outputs when aromatase activity was suppressed over extended observation intervals [1].
Longitudinal follow-up analyses further characterized temporal persistence of estrogen suppression and its relationship to downstream molecular signaling stability. These datasets indicated that aromatase inhibition produced sustained modulation of estrogen-dependent signaling markers beyond the initial exposure window, supporting its use as a long-term endocrine pathway research tool [2].
Recurrence-associated molecular signaling has been examined through comparative endocrine modulation frameworks. In controlled experimental designs, aromatase inhibition via anastrozole has been evaluated alongside selective estrogen receptor modulators to compare differential pathway suppression and feedback regulation.
The IBIS-II DCIS analytical framework generated comparative data examining estrogen-dependent signaling persistence and pathway reactivation under different hormonal modulation strategies. These analyses reported broadly comparable profiles of estrogen-responsive pathway regulation between aromatase inhibition and receptor-level modulation approaches, providing insight into mechanistic differences rather than therapeutic outcomes [3].
Localized estrogen-responsive molecular systems have been widely studied using aromatase inhibition as a primary perturbation method. In structured analytical frameworks such as ATAC, anastrozole has been used to characterize differences in endocrine feedback regulation, estrogen synthesis suppression, and downstream transcriptional modulation when compared to alternative hormonal pathway modifiers.
Sequential modulation studies have further examined phased endocrine pathway suppression, evaluating transitions between different hormonal regulatory states. These investigations generated data describing altered recurrence-associated signaling markers and endocrine response stability following changes in aromatase inhibition timing within experimental systems [4].
Anastrozole has been evaluated in a broader estrogen-regulated signaling context for its ability to sustain aromatase suppression and stabilize estrogen-dependent molecular function. Comparative analytical frameworks analyzed their pathway modulation features as compared to other steroidal and non-steroidal endocrine modulating drugs considering signaling persistence, pathway cross-talk, and regulatory feedback properties.
These studies demonstrated sustained aromatase inhibition patterns and constant modulation of estrogen-regulated molecular markers after long-term exposure. Comparative datasets emphasized differences in signaling kinetics and feedback regulation rather than performance outcomes or clinical implications [5].
Recent studies have investigated the contribution of estrogen metabolism to pulmonary vascular signaling pathways. It has been reported that the expression of aromatase and estrogen biosynthesis is responsible for regulation of vasomotor tone, cellular proliferation and metabolic signaling in pulmonary tissue structures.
In controlled experimental settings, anastrozole has also been used to study effects of estrogen depletion on pulmonary vascular signaling characteristics, expression of endocrine markers and modulation of metabolic pathways. Observed outcomes included altered estrogen concentration profiles and associated changes in downstream signaling markers relevant to vascular physiology research [6].
Anastrozole, a non-steroidal aromatase inhibitor is well-researched in scientific literature for its anti-aromatase activity in the inhibition of estrogen biosynthesis and modulation of endocrine pathway. Its molecular characteristics have contributed to extensive use in the study of mechanisms of hormone-responsive signaling systems, endocrine feedback regulation and estrogen-dependent pathway analysis.
Ongoing investigative efforts continue to examine aromatase inhibition within diverse biochemical and molecular research models, including comparative pathway modulation studies and endocrine signal integration analyses. At Element CRP, anastrozole is supplied exclusively for laboratory, analytical, and educational research purposes. Distribution is restricted to qualified professionals, with no implication of clinical use, therapeutic application, or human consumption. Buy anastrozole only if you are a qualified researcher.
Anastrozole is a non-steroidal small-molecule aromatase inhibitor featuring a triazole core with structural similarities to Letrozole. Its competitive binding behaviour at the CYP19A1 catalytic domain delivers reliable enzyme inhibition kinetics suitable for in vitro pharmacology research applications.
Cell-based research with Anastrozole characterises CYP19A1 (aromatase) inhibition profiles using granulosa cell line models, breast tissue-derived cell preparations, and recombinant enzyme assay systems. Comparative pharmacology with Letrozole and Exemestane maps the structural determinants of binding affinity within the aromatase inhibitor class.
Element CRP supplies this product at 1.5mg/mL × 30mL. USA-manufactured via chemical synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Pre-mixed liquid solution in 30mL or 60mL bottle with dropper; ready for laboratory use. Store at 15-25°C, away from direct light.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
